- Home
- RGC vs DVA Comparison
RGC vs DVA Comparison
Compare RGC & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | DVA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.4B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RGC | DVA |
|---|---|---|
| Price | $17.59 | $121.51 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $145.00 |
| AVG Volume (30 Days) | 210.3K | ★ 972.4K |
| Earning Date | 10-24-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.63 |
| EPS | N/A | ★ 9.76 |
| Revenue | N/A | ★ $13,317,965,000.00 |
| Revenue This Year | N/A | $6.50 |
| Revenue Next Year | N/A | $2.97 |
| P/E Ratio | ★ N/A | $12.43 |
| Revenue Growth | N/A | ★ 5.14 |
| 52 Week Low | $0.09 | $113.97 |
| 52 Week High | $83.60 | $179.60 |
Technical Indicators
Market Signals| Indicator | RGC | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 64.34 | 54.23 |
| Support Level | $16.10 | $115.91 |
| Resistance Level | $17.40 | $122.61 |
| Average True Range (ATR) | 1.62 | 2.30 |
| MACD | 0.63 | 0.54 |
| Stochastic Oscillator | 88.24 | 83.43 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.